The unique transcriptional response produced by concurrent estrogen and progesterone treatment in breast cancer cells results in upregulation of growth factor pathways and switching from a Luminal A to a Basal-like subtype

BACKGROUND: In breast cancer, progesterone receptor (PR) positivity or abundance is positively associated with survival and treatment response. It was initially believed that PR was a useful diagnostic marker of estrogen receptor activity, but increasingly PR has been recognised to play an important...

Descripción completa

Detalles Bibliográficos
Autores principales: Need, Eleanor F., Selth, Luke A., Trotta, Andrew P., Leach, Damien A., Giorgio, Lauren, O’Loughlin, Melissa A., Smith, Eric, Gill, Peter G., Ingman, Wendy V., Graham, J. Dinny, Buchanan, Grant
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620010/
https://www.ncbi.nlm.nih.gov/pubmed/26498662
http://dx.doi.org/10.1186/s12885-015-1819-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620010/
https://www.ncbi.nlm.nih.gov/pubmed/26498662
http://dx.doi.org/10.1186/s12885-015-1819-3

Ejemplares similares